Iovance Biotherapeutics is trading at $11.55, up 5.10%, in pre-market; the immediate reason for the move remains unclear.
- No clear company-specific announcement or other confirmed catalyst for September 29 was identified.
- Recent coverage focused on valuation after a substantial prior rally, rather than a new event explaining the move.
- Major indices were only modestly higher in the supplied market context, and Yahoo Finance’s news page showed no matching fresh catalyst in search results.